SUGAZIDEM® – FORTE Injection

Description

Composition (Per Vial):

• Ceftazidime – 1000 mg

• Tobramycin Sulphate – Equivalent to 120 mg Tobramycin base
  Form: Dry powder for reconstitution
  Route of Administration: Intravenous (IV) or Intramuscular (IM)
  Pack Size: Single-use vial with sterile water for injection
  Category: Broad-spectrum Antibiotic | Anti-Pseudomonal Injection

---

Product Description:

SUGAZIDEM® – FORTE is a potent combination of Ceftazidime, a third-generation cephalosporin, and Tobramycin, a powerful aminoglycoside. Together, they deliver synergistic action against a wide range of aerobic Gram-negative organisms, including Pseudomonas aeruginosa, making it ideal for serious hospital-acquired and resistant infections.

This combination is often used in ICU settings, post-surgical infections, and in patients with sepsis or complicated UTIs, RTIs, and peritonitis.

---

Key Benefits:

• Potent dual-action targeting multi-drug-resistant Gram-negative bacteria

• Excellent efficacy in nosocomial infections, including ventilator-associated pneumonia

• Effective against Pseudomonas, Klebsiella, E. coli, Proteus, and Enterobacter

• Suitable for use in ICU, critical care, and emergency settings

---

How It Works:

• Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing cell lysis.

• Tobramycin binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial death.

The combination provides enhanced bactericidal activity, particularly against difficult-to-treat organisms like Pseudomonas.

---

How to Use:

• Reconstitute with the provided sterile water before use

• Administer via slow IV injection/infusion or deep IM injection

• Typical adult dose: 1 vial every 8–12 hours, adjusted based on renal function and severity

• To be used under supervision in a hospital or ICU setting only

---

Safety Advice:

• Monitor renal function before and during treatment, especially in elderly or renal-impaired patients

• Perform audiometry if long-term use is planned, as aminoglycosides may cause ototoxicity

• Do not mix with other drugs in the same syringe or infusion line

• Always reconstitute freshly before administration

---

Precautions:

• Use with caution in:

  • Patients with existing kidney impairment

  • Concurrent use of other nephrotoxic or ototoxic agents

• Contraindicated in individuals with:

  • Known hypersensitivity to cephalosporins or aminoglycosides

• Prolonged use may lead to secondary fungal or bacterial infections

• Store in a cool, dry place below 25°C

• Use immediately after reconstitution – single-use vial only